Skip to main content
Premium Trial:

Request an Annual Quote

In Print: Last Week's Microarray Papers of Note: Mar 11, 2014

Premium

Development of a novel, quantitative protein microarray platform for the multiplexed serological analysis of autoantibodies to cancer-testis antigens.
Int J Cancer. 2014 Mar 6. [Epub ahead of print]
Beeton-Kempen N,et al.

The authors describe the development of a customizable cancer-testis antigen microarray platform and bioinformatics tools for quantifying anti-cancer testis antigen autoantibody profiles in patient sera. They demonstrate the use of the platform in monitoring the response of a melanoma patient cohort to an experimental therapeutic NY-ESO-1-based cancer vaccine.


Direct covalent attachment of DNA microarrays by rapid thiol-ene "click" chemistry.
Bioconjug Chem. 2014 Mar 4. [Epub ahead of print]
Escorihuela J, et al.

The authors present a strategy for covalently immobilizing DNA onto silicon-based materials using UV-initiated thiol-ene reactions. The authors claim the approach has the advantages of spatially controlled probe anchoring, direct attachment without using cross-linkers, and short irradiation times.


Genomic profiling reveals extensive heterogeneity in somatic DNA copy number aberrations of canine hemangiosarcoma.
Chromosome Res. 2014 Mar 6. [Epub ahead of print]
Thomas R, et al.

The authors performed genome-wide, microarray-based somatic DNA copy number profiling of 75 primary intra-abdominal hemangiosarcomas from five popular dog breeds that are highly predisposed to canine hemangiosarcoma. Copy number alterations involving CDKN2A, VEGFA, and the SKI oncogene were identified as potential driver aberrations of hemangiosarcoma development, highlighting potential targets for therapeutic modulation.